CEVEC
-
Cevec opens US subsidiary
Cevec Pharmaceuticals opens a North American subsidiary in Potomac, Maryland, US. Located close to Washington DC and amidst the Northeast US Bioscience Corridor, the incorporation of the new site reflects Cevec ambition to better serve the growing U…
CEVEC | 26 November 2010
-
Cevec signs agreement with Life Technologies
Cevec Pharmaceuticals announces the signing of a co-exclusive worldwide licensing agreement with Life Technologies. Under the terms of the agreement, they will co-operate to offer optimized expression kits based on Cevec’s proprietary CAP-T cells …
CEVEC | 09 September 2010
-
Cevec Pharmaceuticals and Aragen Bioscience Sign License Agreement
Cevec Pharmaceuticals and Aragen Bioscience have announced the signing of a strategic license agreement. This license enables the latter to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as wel…
CEVEC | 13 May 2010
-
Cevec Signs Agreement with Inno Biologics in Malaysia
Cevec Pharmaceuticals and the contract manufacturer Inno Biologics, Malaysia, have announced the signing of a strategic license agreement. This license enables the latter to offer the full potential of production of their diagnostic and preclinical g…
CEVEC | 31 December 2009
-
InVivo and Cevec Sign Agreement for Production of Recombinant Proteins
Cevec Pharmaceuticals and the contract manufacturer InVivo BioTech Services have announced the signing of a strategic license agreement. This license enables the latter to offer its customers the production of their diagnostic ad preclinical grad…
CEVEC | 11 November 2009
-
Companies Commence Therapeutic Protein Development Program
Alloksys Life Sciences, CEVEC Pharmaceuticals and PharmaCell have announced the start of Theraptech, a €2.4 million ($3 million) therapeutic protein development program subsidized under the European Trans Bio Program. The major objective of the pro…
CEVEC | 06 March 2009
-
New Cevec Pharmaceuticals CEO
Cevec Pharmaceuticals, a biopharmaceutical company specializing in the development of complex therapeutic proteins using their proprietary human cell expression systems, has appointed Rainer Lichtenberger Ph.D., MBA as the new CEO. Lichtenberger w…
CEVEC | 17 October 2008























